Terazosin labels and packages: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
==Labels And | ==Labels And Packages== | ||
PRINCIPAL DISPLAY PANEL TERAZOSIN HYDROCHLORIDE CAPSULES 1 MG | PRINCIPAL DISPLAY PANEL TERAZOSIN HYDROCHLORIDE CAPSULES 1 MG | ||
| Line 29: | Line 29: | ||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TERAZOSIN HYDROCHLORIDE CAPSULE [CARDINAL HEALTH] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=30503dfd-03bd-46d8-8170-d9ed096fd71d | publisher = | date = | accessdate = 7 March 2014 }}</ref> | <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TERAZOSIN HYDROCHLORIDE CAPSULE [CARDINAL HEALTH] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=30503dfd-03bd-46d8-8170-d9ed096fd71d | publisher = | date = | accessdate = 7 March 2014 }}</ref> | ||
==References== | ==References== | ||
Revision as of 19:40, 12 March 2014
| Terazosin |
|---|
| Terazosin®, Hytrin® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Terazosin |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Labels And Packages
PRINCIPAL DISPLAY PANEL TERAZOSIN HYDROCHLORIDE CAPSULES 1 MG
Terazosin Hydrochloride
Capsules 1 mg.*
10 Capsules
 |
PRINCIPAL DISPLAY PANEL TERAZOSIN HYDROCHLORIDE CAPSULES 5 MG
Terazosin Hydrochloride
Capsules 5 mg.*
10 Capsules
 |
References
- ↑ "TERAZOSIN HYDROCHLORIDE CAPSULE [CARDINAL HEALTH]". Retrieved 7 March 2014.